Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
It is not licensed as a lipid-lowering medication, and patients requiring pharmacological cholesterol management should continue statins as recommended by NICE guidance, even whilst taking Saxenda for weight loss
Similar content being viewed by others Main Obesity is a heterogeneous, chronic condition that has grown into an extremely prevalent public health problem 1 and is one of the greatest threats to human health and well-being in the 21st century
Since GLP-1 patches are sold over the counter as dietary supplements, insurance does not cover them
For patients evaluating their options at BODYWELLE in Miami Beach, the most relevant question is not simply which medication produces the greatest weight reduction on paper
Higher levels correlate with lower body fat percentages, particularly around the midsection
